Level C· Early human research exploring benefitsCase Report / SeriesPubMedOpen access

Facial Adipostructuring With Biochemical Modulation in Chronic Peripheral Facial Paralysis: A Case Report.

Calfin H., Riquelme V., Velazco G., Sequera M., Castro C.

Case Report / Series on Face & Skin, published in Cureus (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Cureus (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
42344748
PMCID
PMC13288580
DOI
10.7759/cureus.111350

Abstract (original English)

Chronic peripheral facial paralysis (CPFP) implies a prolonged course without recovery of neuromuscular activity of facial expression and the biological impossibility of restoring spontaneous function. Facial paralyses, most commonly idiopathic in origin, are graded using the House-Brackmann (HB) scale, where grade I represents normal function and grades II through VI indicate progressively greater functional compromise. Furthermore, CPFP lacks satisfactory therapeutic options, and conventional strategies, botulinum toxin and surgical reanimation, neither address the collapse of facial structural support nor the dysfunction of dermal white adipose tissue (dWAT) that accompanies chronic denervation. This report presents a treatment strategy for patients with CPFP consisting of Facial Adipostructuring (AEF), a biomechanical reorganization of fat compartments via cannula-based mechanotransduction without tissue extraction, combined with biochemical modulation using dimethylaminoethanol (DMAE), organic silicon, and acetyl hexapeptide-38. The patient progressed from HB grade IV to grade I over three biweekly sessions, with improvement sustained at nine-month follow-up without additional interventions. The changes observed were consistent with improvements on the HB functional scale and were documented through standardized clinical photography. This treatment represents a minimally i

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research